CreativeOne Wealth LLC lessened its position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) by 21.1% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 27,492 shares of the company’s stock after selling 7,360 shares during the quarter. CreativeOne Wealth LLC’s holdings in Invesco Biotechnology & Genome ETF were worth $1,919,000 as of its most recent filing with the SEC.
Other hedge funds have also made changes to their positions in the company. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $26,000. Howe & Rusling Inc. acquired a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $31,000. GPS Wealth Strategies Group LLC acquired a new position in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $30,000. UMB Bank n.a. acquired a new position in Invesco Biotechnology & Genome ETF in the 2nd quarter valued at approximately $31,000. Finally, Carnegie Investment Counsel acquired a new position in Invesco Biotechnology & Genome ETF in the 3rd quarter valued at approximately $204,000.
Invesco Biotechnology & Genome ETF Stock Performance
Invesco Biotechnology & Genome ETF stock opened at $70.56 on Friday. The firm has a market cap of $285.08 million, a PE ratio of 17.12 and a beta of 0.88. The firm’s 50 day moving average price is $69.23 and its two-hundred day moving average price is $67.99. Invesco Biotechnology & Genome ETF has a twelve month low of $56.21 and a twelve month high of $72.84.
Invesco Biotechnology & Genome ETF Profile
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Further Reading
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- What is a buyback in stocks? A comprehensive guide for investors
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- What Does Downgrade Mean in Investing?
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
